Company Overview and News

6
PARR / Par Pacific Holdings Inc. null

2018-06-14 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,B]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
PARR

14
This Week’s Rising Refining and Marketing Energy Stocks

2018-05-27 marketrealist
In this part of our series, we’ll look at the top-percentage gainers from the US refining and marketing sector this week. To compile the list of top refining and marketing gainers, we’ve selected refining and marketing companies with market capitalizations greater than $100 million and average trading volume greater than 100,000 shares last week.
PBF PARR HFC CVRR VLO

6
3 Refiners to Profit From Higher Gasoline Prices and Demand

2018-05-27 investorplace
With gasoline price inching upward in recent weeks, the cost to fill up over Memorial Day weekend this year will be dearer than it was a year ago, and the costliest it has been in more than four years.
PARR DK HFC

6
PARR / Par Pacific Holdings Inc. 8-K (Current Report)

2018-05-24 sec.gov
Document UNITED STATES SECURITIES AND
PARR

16
6 Energy Stocks That Crushed Estimates This Earnings Season

2018-05-23 zacks
The first-quarter reporting cycle is almost over. During a reporting cycle, investors keep a tab of the companies delivering earnings beat. Earnings theoretically determine the growth or contraction of companies as well as their stocks. Speculations regarding earnings beat or miss can either cheer investors or upset them to the point of a hasty sell-off. Q1 Earnings Season Wrapping Up As of May 17, 461 S&P 500 members reported Q1 results that combined account for 95.
ECR PARR CQP TOL LNG HFC CRK WTTR LNG

6
PARR / Par Pacific Holdings Inc. S-8

2018-05-18 sec.gov
S-8 As filed with the Securities and Exchange Commission on May 18, 2018 Registration No. 333-
PARR

6
PARR / Par Pacific Holdings Inc. 10-Q (Quarterly Report)

2018-05-10 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PARR

6
PARR / Par Pacific Holdings Inc. 8-K (Current Report)

2018-05-10 sec.gov
Document UNITED STATES
PARR

6
Par Pacific Holdings' (PARR) CEO William Pate on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Par Pacific Holdings, Inc. (NYSEMKT:PARR) Q1 2018 Earnings Conference Call May 9, 2018 12:00 PM ET
PARR

6
PARR / Par Pacific Holdings Inc. 8-K (Current Report)

2018-05-09 sec.gov
Document UNITED STATES
PARR

7
HollyFrontier (HFC) Q1 Earnings Surpass on Higher Margins

2018-05-08 zacks
HollyFrontier Corporation (HFC - Free Report) reported first-quarter 2018 net income per share (excluding special items) of 77 cents, significantly above the Zacks Consensus Estimate of 37 cents. The better-than-anticipated results can be attributed to higher-than-expected refining margins and refined product sales. Notably, the refining margins in the quarter stood at $12.83 a barrel compared with the Zacks Consensus Estimate of $10.
HEP PARR DK HFC

20
Christopher Micklas Joins Houston Wire & Cable Company as the New Vice President and Chief Financial Officer

2018-04-13 globenewswire
HOUSTON, April 13, 2018 (GLOBE NEWSWIRE) -- Houston Wire & Cable Company (Nasdaq:HWCC), a leading supplier of electrical cable, steel wire rope, and stainless steel fasteners, announced today the appointment of Mr. Christopher M. Micklas as its Vice President and Chief Financial Officer, effective April 16, 2018. Mr. Micklas will also serve as the Company’s principal accounting officer.
PARR BRGXF BG GEC GE BRGYY GNE

6
9
Institutional Investors’ Activity for DK, PARR, SU, and PBR

2018-03-29 editors.aws.marketrealist
In 4Q17, 107 funds were buyers of Delek US Holdings (DK) stock, and 85 funds were sellers. Ttotal buying funds outnumbered total selling funds by 22. As of December 31, 2017, 195 13F filers held DK in their portfolios, and only one of those filers had DK in its top ten holdings.
PARR DK SU SU

6

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to PARR / Par Pacific Holdings Inc. on message board site Silicon Investor.

Chaparral Steel Barronu0027s Sparrows!!!!
Chaparral (CHAR) - Russia (Kazakhstan) oil play Adelphia Communications: Crumbs for the Equity Sparrows?
Polly the Parrot- Queen of test threads Chaparral Resources - CHAR
SAILORS, BOATERS AND PARROTHEADS UNITE!!! Bullet Sports International Inc. Nasdaq:PARR
THE NEW BULLET GOLF ( PARR )
CUSIP: 69888T207